Approval · Notice of Compliance 22812 · 2019
LOVENOX: Notice of Compliance 22812
Issued October 18, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22812
- Date
- October 18, 2019
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVENOX | Not yet assigned | — |
Medicinal ingredients
- ENOXAPARIN SODIUM 30 MG per 0.3ML
- ENOXAPARIN SODIUM 40 MG per 0.4ML
- ENOXAPARIN SODIUM 60 MG per 0.6ML
- ENOXAPARIN SODIUM 80 MG per 0.8ML
- ENOXAPARIN SODIUM 100 MG per ML